Triptans

Study Reference
Bérard, 2012

Bérard A Dihydroergotamine (DHE) use during gestation and the risk of adverse pregnancy outcomes. Headache 2012;52:1085-93

de Jonge - Sumatriptan, 2013

de Jonge Identifying associations between maternal medication use and birth defects using a case-population approach: an exploratory study on signal detection. Drug Saf 2013; 36:1069-78

Harris (Control exposed before pregnancy), 2018

Harris Prenatal triptan exposure and neurodevelopmental outcomes in 5-year-old children: Follow-up from the Norwegian Mother and Child Cohort Study. Paediatr Perinat Epidemiol 2018; 32:247-255

Harris (Control mainly exposed to other treatments, sick), 2018

Harris Prenatal triptan exposure and neurodevelopmental outcomes in 5-year-old children: Follow-up from the Norwegian Mother and Child Cohort Study. Paediatr Perinat Epidemiol 2018; 32:247-255

Källén (control exposed to ergots), 2011

Kallen B Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. Drug Saf 2011;34:691-703

Källén (control unexposed, disease free), 2011

Kallen B Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. Drug Saf 2011;34:691-703

Kallen - Sumatriptan, 2001

Kallen Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 2001; 41:351-6

Nezvalová-Henriksen (Control unexposed, disease free), 2013

Nezvalova-Henriksen K Triptan safety during pregnancy: a Norwegian population registry study. Eur J Epidemiol 2013;28:759-69

Nezvalová-Henriksen (Control unexposed, sick), 2013

Nezvalova-Henriksen K Triptan safety during pregnancy: a Norwegian population registry study. Eur J Epidemiol 2013;28:759-69

O'Quinn - Sumatriptan, 1999

O'Quinn Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. Arch. Gynecol. Obstet. 1999; 263:7-12

Olesen - Sumatriptan (Control unexposed, disease free), 2000

Olesen C Pregnancy outcome following prescription for sumatriptan. Headache 2000;40:20-4

Olesen - Sumatriptan (Control unexposed, sick), 2000

Olesen C Pregnancy outcome following prescription for sumatriptan. Headache 2000;40:20-4

Shuhaiber - Sumatriptan (Control exposed to other treatments), 1998

Shuhaiber S Pregnancy outcome following first trimester exposure to sumatriptan. Neurology 1998;51:581-3

Shuhaiber - Sumatriptan (Control unexposed, disease free), 1998

Shuhaiber S Pregnancy outcome following first trimester exposure to sumatriptan. Neurology 1998;51:581-3

Spielmann (Control mainly exposed other treatments, sick), 2017

Spielmann K Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study. Cephalalgia 2017;:333102417724152

Spielmann (Control unexposed, disease free), 2017

Spielmann K Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study. Cephalalgia 2017;:333102417724152

Werler, 2009

Werler Is there epidemiologic evidence to support vascular disruption as a pathogenesis of gastroschisis? Am. J. Med. Genet. A 2009; 149A:1399-406

Wood 2016a (Control exposed only before pregnancy), 2016

Wood ME Prenatal Triptan Exposure and Internalising and Externalising Behaviour Problems in 3-Year-Old Children: Results from the Norwegian Mother and Child Cohort Study. Paediatr Perinat Epidemiol 2016;30:190-200

Wood 2016a (Control mainly exposed to other treatments, sick), 2016

Wood ME Prenatal Triptan Exposure and Internalising and Externalising Behaviour Problems in 3-Year-Old Children: Results from the Norwegian Mother and Child Cohort Study. Paediatr Perinat Epidemiol 2016;30:190-200

Wood 2016a (Control unexposed, disease free), 2016

Wood ME Prenatal Triptan Exposure and Internalising and Externalising Behaviour Problems in 3-Year-Old Children: Results from the Norwegian Mother and Child Cohort Study. Paediatr Perinat Epidemiol 2016;30:190-200

Wood 2016b, 2016

Wood Prenatal triptan exposure and parent-reported early childhood neurodevelopmental outcomes: an application of propensity score calibration to adjust for unmeasured confounding by migraine severity. Pharmacoepidemiol Drug Saf 2016; 25:493-502